Airway remodelling in asthma and novel therapy

Asian Pacific Journal of Allergy and Immunology

Volumn 31, Issue 1, 2013, Pages 3-10

  Manuyakorn, Wiparat ^a   Howarth, Peter H ^b   Holgate, Stephen T ^b  

^a MAHIDOL UNIVERSITY   (Thailand)

^b UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

Author keywords

Airway structural changes; Asthma; Asthma therapy; Physical forces; Remodelling

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BUDESONIDE; BUDESONIDE PLUS FORMOTEROL; COLLAGEN TYPE 1; COLLAGEN TYPE 3; COLLAGEN TYPE 4; COLLAGEN TYPE 5; CONNECTIVE TISSUE GROWTH FACTOR; CORTICOSTEROID; EPIDERMAL GROWTH FACTOR RECEPTOR; FIBRONECTIN; FLUTICASONE PROPIONATE; FORMOTEROL; INTERLEUKIN 13; INTERLEUKIN 5; LAMININ; METHACHOLINE; MONTELUKAST; MUSCARINIC M3 RECEPTOR; OMALIZUMAB; PROTEIN TYROSINE KINASE INHIBITOR; PROTEOGLYCAN; SALMETEROL; THROMBOPLASTIN; TIOTROPIUM BROMIDE; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; UNINDEXED DRUG; VASCULOTROPIN; VITAMIN D;

AIRWAY OBSTRUCTION; AIRWAY REMODELING; ANGIOGENESIS; ASTHMA; BLOOD FLOW; BLOOD VESSEL PERMEABILITY; BREATHING MUSCLE; CELL DAMAGE; DISEASE COURSE; DISEASE SEVERITY; DRUG MEGADOSE; EDEMA; FIBROSIS; HIGH RESOLUTION COMPUTER TOMOGRAPHY; HUMAN; HYPERPLASIA; HYPERTROPHY; IMMUNOHISTOCHEMISTRY; METAPLASIA; MULTICENTER STUDY (TOPIC); MUSCLE MASS; NONHUMAN; RESPIRATORY TRACT INFLAMMATION; REVIEW; SMOOTH MUSCLE CONTRACTION;

AIRWAY REMODELING; ANTI-ASTHMATIC AGENTS; ASTHMA; HUMANS; RESPIRATORY MUCOSA;

EID: 84873556164     PISSN: 0125877X     EISSN: 22288694     Source Type: Journal    
DOI: None     Document Type: Review

References (50)

1. Holgate ST. Pathogenesis of asthma. Clin Exp Allergy. 2008;38:872-97.
2. Guilbert TW, Morgan WJ, Zeiger RS, Mauger DT, Boehmer SJ, Szefler SJ, et al. Long-term inhaled corticosteroids in preschool children at high risk for asthma. N Engl J Med. 2006;354:1985-97.
3. Sears MR, Greene JM, Willan AR, Wiecek EM, Taylor DR, Flannery EM, et al. A longitudinal, population-based, cohort study of childhood asthma followed to adulthood. N Engl J Med. 2003;349:1414-22.
4. Bergeron C, Boulet LP. Structural changes in airway diseases: characteristics, mechanisms, consequences, and pharmacologic modulation. Chest. 2006;129:1068-87.
5. Roche WR, Beasley R, Williams JH, Holgate ST. Subepithelial fibrosis in the bronchi of asthmatics. Lancet. 1989;1:520-4.
6. Hostettler KE, Roth M, Burgess JK, Gencay MM, Gambazzi F, Black JL, et al. Airway epithelium-derived transforming growth factor-beta is a regulator of fibroblast proliferation in both fibrotic and normal subjects. Clin Exp Allergy. 2008;38:1309-17.
7. Chetta A, Foresi A, Del DM, Bertorelli G, Pesci A, Olivieri D. Airways remodelling is a distinctive feature of asthma and is related to severity of disease. Chest. 1997;111:852-7.
8. Niimi A, Matsumoto H, Takemura M, Ueda T, Chin K, Mishima M. Relationship of airway wall thickness to airway sensitivity and airway reactivity in asthma. Am J Respir Crit Care Med. 2003;168:983-8.
9. Jain N, Covar RA, Gleason MC, Newell JD, Jr., Gelfand EW, Spahn JD. Quantitative computed tomography detects peripheral airway disease in asthmatic children. Pediatr Pulmonol. 2005;40:211-8.
10. James A. Remodelling of airway smooth muscle in asthma: what sort do you have? Clin Exp Allergy. 2005;35:703-7.
11. Ebina M, Yaegashi H, Chiba R, Takahashi T, Motomiya M, Tanemura M. Hyperreactive site in the airway tree of asthmatic patients revealed by thickening of bronchial muscles. A morphometric study. Am Rev Respir Dis. 1990;141:1327-32.
12. Al-Muhsen S, Johnson JR, Hamid Q. Remodelling in asthma. J Allergy Clin Immunol. 2011.
13. Kazi AS, Lotfi S, Goncharova EA, Tliba O, Amrani Y, Krymskaya VP, et al. Vascular endothelial growth factor-induced secretion of fibronectin is ERK dependent. Am J Physiol Lung Cell Mol Physiol. 2004;286:L539-45.
14. Ribatti D, Puxeddu I, Crivellato E, Nico B, Vacca A, Levi-Schaffer F. Angiogenesis in asthma. Clin Exp Allergy. 2009;39:1815-21.
15. Park JA, Sharif AS, Tschumperlin DJ, Lau L, Limbrey R, Howarth P, et al. Tissue factor-bearing exosome secretion from human mechanically stimulated bronchial epithelial cells in vitro and in vivo. J Allergy Clin Immunol. 2012.
16. Turato G, Barbato A, Baraldo S, Zanin ME, Bazzan E, Lokar Oliani K, et al. Nonatopic children with multitrigger wheezing have airway pathology comparable to atopic asthma. Am J Respir Crit Care Med. 2008;178:476-82.
17. Fedorov IA, Wilson SJ, Davies DE, Holgate ST. Epithelial stress and structural remodelling in childhood asthma. Thorax. 2005;60:389-94.
18. Bossley CJ, Fleming L, Gupta A, Regamey N, Frith J, Oates T, et al. Pediatric severe asthma is characterized by eosinophilia and remodelling without T(H)2 cytokines. J Allergy Clin Immunol. 2012;129:974-82.
19. Saglani S, Payne DN, Zhu J, Wang Z, Nicholson AG, Bush A, et al. Early detection of airway wall remodelling and eosinophilic inflammation in preschool wheezers. Am J Respir Crit Care Med. 2007;176:858-64.
20. Bishop JE, Mitchell JJ, Absher PM, Baldor L, Geller HA, Woodcock-Mitchell J, et al. Cyclic mechanical deformation stimulates human lung fibroblast proliferation and autocrine growth factor activity. Am J Respir Cell Mol Biol. 1993;9:126-33.
21. Choe MM, Sporn PH, Swartz MA. An in vitro airway wall model of remodelling. Am J Physiol Lung Cell Mol Physiol. 2003;285:L427-33.
22. Hasaneen NA, Zucker S, Cao J, Chiarelli C, Panettieri RA, Foda HD. Cyclic mechanical strain-induced proliferation and migration of human airway smooth muscle cells: role of EMMPRIN and MMPs. FASEB J. 2005;19:1507-9.
23. Hasaneen NA, Zucker S, Lin RZ, Vaday GG, Panettieri RA, Foda HD. Angiogenesis is induced by airway smooth muscle strain. Am J Physiol Lung Cell Mol Physiol. 2007;293:L1059-68.
24. Matsumoto H, Niimi A, Tabuena RP, Takemura M, Ueda T, Yamaguchi M, et al. Airway wall thickening in patients with cough variant asthma and nonasthmatic chronic cough. Chest. 2007;131:1042-9.
25. Laitinen LA, Laitinen A, Haahtela T. A comparative study of the effects of an inhaled corticosteroid, budesonide, and a beta 2-agonist, terbutaline, on airway inflammation in newly diagnosed asthma: a randomized, double-blind, parallel-group controlled trial. J Allergy Clin Immunol. 1992;90:32-42.
26. Roth M, Johnson PR, Borger P, Bihl MP, Rüdiger JJ, King GG, et al. Dysfunctional interaction of C/EBPalpha and the glucocorticoid receptor in asthmatic bronchial smooth-muscle cells. N Engl J Med. 2004;351:560-74.
27. Durrani SR, Viswanathan RK, Busse WW. What effect does asthma treatment have on airway remodelling? Current perspectives. J Allergy Clin Immunol. 2011;128:439-48.
28. Chetta A, Zanini A, Foresi A, D'Ippolito R, Tipa A, Castagnaro A, et al. Vascular endothelial growth factor up-regulation and bronchial wall remodelling in asthma. Clin Exp Allergy. 2005;35:1437-42.
29. Kelly HW, Sternberg AL, Lescher R, Fuhlbrigge AL, Williams P, Zeiger RS, et al. Effect of inhaled glucocorticoids in childhood on adult height. N Engl J Med. 2012;367:904-12.
30. Goulet S, Bihl MP, Gambazzi F, Tamm M, Roth M. Opposite effect of corticosteroids and long-acting beta(2)-agonists on serum and TGF-beta(1)-induced extracellular matrix deposition by primary human lung fibroblasts. J Cell Physiol. 2007;210:167-76.
31. Wang K, Liu CT, Wu YH, Feng YL, Bai HL, Ma ES, et al. Effects of formoterol-budesonide on airway remodelling in patients with moderate asthma. Acta Pharmacol Sin. 2011;32:126-32.
32. Henderson WR, Jr., Chiang GK, Tien YT, Chi EY. Reversal of allergen-induced airway remodelling by CysLT1 receptor blockade. Am J Respir Crit Care Med. 2006;173:718-28.
33. Ohta S, Oda N, Yokoe T, Tanaka A, Yamamoto Y, Watanabe Y, et al. Effect of tiotropium bromide on airway inflammation and remodelling in a mouse model of asthma. Clin Exp Allergy. 2010;40:1266-75.
34. Kerstjens HA, Engel M, Dahl R, Paggiaro P, Beck E, Vandewalker M, S, et al. Tiotropium in asthma poorly controlled with standard combination therapy. N Engl J Med. 2012;367:1198-207.
35. Hoshino M, Ohtawa J. Effects of adding omalizumab, an anti-immunoglobulin E antibody, on airway wall thickening in asthma. Respiration. 2012;83:520-8.
36. Riccio AM, Dal Negro RW, Micheletto C, De Ferrari L, Folli C, Chiappori A, et al. Omalizumab modulates bronchial reticular basement membrane thickness and eosinophil infiltration in severe persistent allergic asthma patients. Int J Immunopathol Pharmacol. 2012;25:475-84.
37. Damera G, Fogle HW, Lim P, Goncharova EA, Zhao H, Banerjee A, et al. Vitamin D inhibits growth of human airway smooth muscle cells through growth factor-induced phosphorylation of retinoblastoma protein and checkpoint kinase 1. Br J Pharmacol. 2009;158:1429-41.
38. Gupta A, Sjoukes A, Richards D, Banya W, Hawrylowicz C, Bush A, et al. Relationship between serum vitamin D, disease severity, and airway remodelling in children with asthma. Am J Respir Crit Care Med. 2011;184:1342-9.
39. Flood-Page P, Menzies-Gow A, Phipps S, Ying S, Wangoo A, Ludwig MS, et al. Anti-IL-5 treatment reduces deposition of ECM proteins in the bronchial subepithelial basement membrane of mild atopic asthmatics. J Clin Invest. 2003;112:1029-36.
40. Haldar P, Brightling CE, Hargadon B, Gupta S, Monteiro W, Sousa A, et al. Mepolizumab and exacerbations of refractory eosinophilic asthma. N Engl J Med. 2009;360:973-84.
41. Nair P, Pizzichini MM, Kjarsgaard M, Inman MD, Efthimiadis A, Pizzichini E, et al. Mepolizumab for prednisone-dependent asthma with sputum eosinophilia. N Engl J Med. 2009;360:985-93.
42. Pavord ID, Korn S, Howarth P, Inman MD, Efthimiadis A, Pizzichini E, et al. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet. 2012;380:651-9.
43. Ingram JL, Kraft M. IL-13 in asthma and allergic disease: Asthma phenotypes and targeted therapies. J Allergy Clin Immunol. 2012;130:829-42.
44. Corren J, Lemanske RF, Hanania NA, Korenblat PE, Parsey MV, Arron JR, et al. Lebrikizumab treatment in adults with asthma. N Engl J Med. 2011;365:1088-98.
45. Brightling C, Berry M, Amrani Y. Targeting TNF-alpha: a novel therapeutic approach for asthma. J Allergy Clin Immunol. 2008;121:5-10.
46. Berry MA, Hargadon B, Shelley M, Parker D, Shaw DE, Green RH, et al. Evidence of a role of tumor necrosis factor alpha in refractory asthma. N Engl J Med. 2006;354:697-708.
47. Wenzel SE, Barnes PJ, Bleecker ER, Bousquet J, Busse W, Dahlén SE, et al. A randomized, double-blind, placebo-controlled study of tumor necrosis factor-alpha blockade in severe persistent asthma. Am J Respir Crit Care Med. 2009;179:549-58.
48. Guntur VP, Reinero CR. The potential use of tyrosine kinase inhibitors in severe asthma. Curr Opin Allergy Clin Immunol. 2012;12:68-75.
49. Bosse Y, Thompson C, Stankova J, Rola-Pleszczynski M. Fibroblast growth factor 2 and transforming growth factor beta1 synergism in human bronchial smooth muscle cell proliferation. Am J Respir Cell Mol Biol. 2006;34:746-53.
50. Lee-Fowler TM, Guntur V, Dodam J, Cohn LA, DeClue AE, Reinero CR. The tyrosine kinase inhibitor masitinib blunts airway inflammation and improves associated lung mechanics in a feline model of chronic allergic asthma. Int Arch Allergy Immunol. 2012;158:369-74.